A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507321-42-00

Acronym

SGR-2921-101

Enrollment

Registered

2024-01-31

Start date

2024-02-15

Completion date

2025-08-14

Last updated

2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia (AML), Myelodysplastic syndrome (MDS)

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026